All Stories

Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet

The company is handing back the tumor candidate it snapped up in 2021 after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody.

Mar 3, 2025 - 17:12
 0
Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet
The company is handing back the tumor candidate it snapped up in 2021 after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody.
Read More

Tags:

Previous Article

Consumer spending falls, highlighting fading confidence

Next Article

Human medicines European public assessment report (EPAR): Xoterna Breezhaler, in...

Related Posts

AbbVie pays Gubra $350M to make late play for obesity space

AbbVie pays Gubra $350M to make late play for obesity s...

Mar 3, 2025  0

Oligonucleotide stops gene expansion process that drives Huntington’s disease: study

Oligonucleotide stops gene expansion process that drive...

Feb 12, 2025  0

Research reveals ‘ticking DNA clock’ behind Huntington’s disease

Research reveals ‘ticking DNA clock’ behind Huntington’...

Feb 28, 2025  0